Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Completed NCT02765802

A Study to Evaluate Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection

Conditions: Hepatitis D, Chronic

Sex: All

Ages: 18 Years – 65 Years

Healthy volunteers: No

Phase: PHASE2

Enrollment: 33

Sponsor: EIT Pharma, Inc.

Location: Soroka Medical Center Beersheba

Summary

To evaluate safety and tolerability of lambda over a 48-week treatment period in HDV patients.

Eligibility Criteria

Inclusion Criteria: * Chronic HDV infection of at least 6 months' duration documented by a positive HDV antibody (Ab) test, detectable and quantifiable HDV RNA by qPCR at study entry * Serum alanine aminotransferase (ALT) \> upper limit of the normal range (ULN) and \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT02765802). StuddyBuddy aggregates publicly available trial information.